February 9, 2010 Sweden
Company analysis by Redeye
Diamyd Medical: Gearing up in the USA
An undramatic quarter with income and profit in line with expectations. The finances are sufficiently strong for the company to analyse current Phase III trials without a partner. The European Phase III trial of Diamyd
® is fully recruited and the results are expected at the beginning of the second quarter next year. We expect US registration trial is lagging six months behind with results in the second half of 2011. The market has begun pricing a success of the current Phase III trials. Given promising Phase II results we anticipate continued speculation on the company's shares ahead of the Phase III data due in April next year.
Read more and download the analysis here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.